Physician profile
Anna V Longacre
NPI 1831118405
$18,731.52
in general payments reported to CMS, 2019-2025
45 companies · $4,378 in 2025
The $4,378 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,607 · 2020: $1,220 · 2021: $1,828 · 2022: $2,786 · 2023: $3,161 · 2024: $3,752 · 2025: $4,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $93.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,196.07 |
| Education | $93.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,219.04 | 2019-2025 | |
| Janssen Biotech, INC. | $1,794.76 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,454.10 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $1,219.69 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $723.19 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $713.71 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Intercept Pharmaceuticals, INC. | $680.45 | 2019-2024 | Ocaliva |
| Pfizer INC. | $639.26 | 2019-2025 | |
| Ardelyx, INC. | $614.34 | 2022-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $578.28 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $541.21 | 2019-2025 | Epclusa, Livdelzi |
| Lilly USA, LLC | $507.91 | 2024-2025 | Omvoh |
| Celgene Corporation | $455.19 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $355.82 | 2019-2025 | |
| Madrigal Pharmaceuticals | $348.42 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $333.68 | 2019-2023 | Dificid, Zinplava |
| Aimmune Therapeutics, INC. | $312.57 | 2024-2025 | Zenpep, Vowst |
| Mallinckrodt Hospital Products INC. | $295.07 | 2024-2025 | Terlivaz |
| Qol Medical, LLC | $259.37 | 2019-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $198.75 | 2024-2025 | Voquezna |
| Medtronic, INC. | $148.81 | 2022-2025 | Interstim |
| Medtronic USA, INC. | $148.19 | 2019 | |
| Enterra Medical, INC. | $140.87 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $108.78 | 2024 | Zeposia |
| Dova Pharmaceuticals | $95.71 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $89.02 | 2024-2025 | Iqirvo |
| Celltrion USA INC. | $83.51 | 2023-2024 | Zymfentra, Yuflyma |
| Nestle Healthcare Nutrition INC. | $78.42 | 2021-2023 | |
| Alfasigma USA, INC. | $69.41 | 2020 | |
| Redhill Biopharma INC. | $62.71 | 2020-2022 | |
| Organon LLC | $56.90 | 2021-2025 | Renflexis, Hadlima |
| Allergan, INC. | $52.55 | 2019-2020 | |
| Novo Nordisk INC | $51.99 | 2025 | Wegovy |
| Ucb, INC. | $45.76 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $36.83 | 2020-2023 | Rebyota |
| Mylan Institutional INC. | $34.75 | 2023 | Hulio |
| Alexion Pharmaceuticals, INC. | $33.66 | 2020-2022 | |
| Boston Scientific Corporation | $27.16 | 2019-2022 | |
| Romark Laboratories, Lc | $25.75 | 2019-2020 | |
| Amgen INC. | $22.20 | 2023 | Amjevita, Avsola |
| Vivus LLC | $19.32 | 2025 | Pancreaze |
| Biocon Biologics INC | $17.01 | 2025 | Yesintek |
| Merit Medical Systems INC | $15.43 | 2025 | Endomaxx Stent and Delivery System, Esophyx |
| Ethicon US, LLC | $11.49 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Longacre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.